 The study developed a bone-targeting therapeutic agent by tagging acidic oligoptide to a non-membrane-bound form of RAGE, endogenous secretory RAGE, SIG, functioning as a decoy receptor which was assessed in a murine model of collagen-induced arthritis, CIA. The study found that D6-SIG, the tagged SIG, was localized to mineralized regions in bone and significantly ameliorated inflammatory arthritis, synovial hyperplasia, cartilage destruction and bone destruction. Additionally, D6-SIG reduced plasma levels of pro-inflammatory cytokines including TNF, Illinois 1 and Illinois 6, while untagged SIG showed little effectiveness. The study suggests that D6-SIG enhances drug delivery to bone, leading to rescue of clinical and pathological lesions in murine CIA. This article was authored by Totsuo Tokahoshi, Sayaka Katsuta, Yusuka Tomua and others.